Payment overview · 2025
General Payments
$770.12
43 reported records · 15 companies
Healthcare provider profile · identity verified
Patrick J Kendell, MD
Allopathic & Osteopathic Physicians|Family Medicine · LAYTON, UT · NPI 1225324973
Verified facts
What the public records show
CMS Open Payments records show Patrick J Kendell, MD received $770.12 in general payments during 2025 across 43 reported records.
Amgen Inc. accounted for 22.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $171.63 | 22.3% | 11 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $107.05 | 13.9% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $96.95 | 12.6% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $66.71 | 8.7% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $52.07 | 6.8% | 2 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $46.97 | 6.1% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $35.92 | 4.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.96 | 4.5% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.87 | 4.3% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $30.07 | 3.9% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.76 | 3.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.68 | 2.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $16.58 | 2.1% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $15.92 | 2.1% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $14.98 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $770.12 | 43 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $148.02 | 8 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $116.85 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $55.98 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $54.78 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $54.78 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $52.07 | 2 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $46.97 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.64 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $35.92 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $35.51 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $34.96 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $34.96 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $32.87 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $31.20 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $30.07 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.76 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $22.68 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $22.68 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 77 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
77 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
77 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 290 | 63 |
| Atorvastatin Calcium | Atorvastatin Calcium | 260 | 80 |
| Omeprazole | Omeprazole | 201 | 51 |
| Lisinopril | Lisinopril | 165 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 162 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 142 | 43 |
| Losartan Potassium | Losartan Potassium | 137 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 126 | 37 |
| Metformin Hcl Er | Metformin Hcl | 117 | 42 |
| Naproxen | Naproxen | 107 | 41 |
| Alendronate Sodium | Alendronate Sodium | 104 | 37 |
| Trazodone Hcl | Trazodone Hcl | 99 | 34 |
| Tramadol Hcl | Tramadol Hcl | 92 | 19 |
| Gabapentin | Gabapentin | 90 | 27 |
| Simvastatin | Simvastatin | 89 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 88 | 32 |
| Glimepiride | Glimepiride | 87 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 86 | 28 |
| Celecoxib | Celecoxib | 84 | 27 |
| Jardiance | Empagliflozin | 77 | 19 |
| Ozempic | Semaglutide | 75 | 13 |
| Furosemide | Furosemide | 69 | 25 |
| Potassium Chloride | Potassium Chloride | 65 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 58 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | suppressed |
| Allopurinol | Allopurinol | 52 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 50 | 29 |
| Amitriptyline Hcl | Amitriptyline Hcl | 48 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 47 | 15 |
| Clonazepam | Clonazepam | 45 | suppressed |
| Famotidine | Famotidine | 42 | 12 |
| Metformin Hcl | Metformin Hcl | 42 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 13 |
| Spironolactone | Spironolactone | 39 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Ketoconazole | Ketoconazole | 37 | 22 |
| Mupirocin | Mupirocin | 37 | 29 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 35 | 11 |
| Bupropion Xl | Bupropion Hcl | 34 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Carvedilol | Carvedilol | 31 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 31 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 24 |
| Prednisone | Prednisone | 30 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | 11 |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | 11 |
| Ondansetron Odt | Ondansetron | 26 | suppressed |
| Olanzapine | Olanzapine | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 22 |
| Sertraline Hcl | Sertraline Hcl | 24 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 16 |
| Eliquis | Apixaban | 23 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 23 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 21 | 15 |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 15 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Paliperidone Er | Paliperidone | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Dayvigo | Lemborexant | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $770.12 · 43 records | Amgen Inc. | AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, Dexcom G6 Transmitter, EVENITY, GEMTESA, Heplisav-B, INGREZZA, JARDIANCE, MOUNJARO, OTEZLA, PROLIA, QULIPTA, REPATHA, REXULTI, SHINGRIX, TZIELD, UBRELVY, VOQUEZNA, ZEPBOUND, ZORYVE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error